SuperworthCharles River Laboratories International market cap CRL
Share price times shares outstanding: what the whole company sells for, since 2010.
- Today, Oct 23, 2026
- $16.5B
- Highest close in our data
- $23.1B
- Sep 2021
Charles River Laboratories International is worth $16.5B at the close on Oct 23, 2026, at $345.37 a share.
That is up 70% over the last year and down 27% over five years.
Its highest close in our data was $23.1B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $16.5B | $7.3B | $16.5B | +64% |
| 2025 | $10B | $5.1B | $10B | +5% |
| 2024 | $9.5B | $9.3B | $14B | −21% |
| 2023 | $12.1B | $8.8B | $12.7B | +9% |
| 2022 | $11.1B | $9.5B | $17.9B | −42% |
| 2021 | $19B | $12.9B | $23.1B | +53% |
| 2020 | $12.4B | $5.2B | $12.5B | +68% |
| 2019 | $7.4B | $5.3B | $7.4B | +38% |
| 2018 | $5.4B | $4.7B | $6.6B | +4% |
| 2017 | $5.2B | $3.7B | $5.6B | +44% |
| 2016 | $3.6B | $3.2B | $4.1B | −4% |
| 2015 | $3.7B | $3B | $4B | +24% |
| 2014 | $3B | $2.5B | $3B | +18% |
| 2013 | $2.6B | $1.9B | $2.6B | +43% |
| 2012 | $1.8B | $1.4B | $2B | +33% |
| 2011 | $1.4B | $1.3B | $2.4B | −34% |
| 2010 | $2.1B | $1.8B | $2.2B | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Charles River Laboratories International's size, closest first, today.
| Company | Market cap |
|---|---|
| CRLCharles River Laboratories International | $16.5B |
| RVTYRevvity | $17.7B |
| MEDPMedpace | $18.7B |
| LHLabcorp | $26.7B |
| DGXQuest Diagnostics | $26.7B |
| BIOBio-Rad Laboratories | $9.9B |
| CAICaris Life Sciences | $9B |
| MTDMettler-Toledo International | $33.5B |
| ILMNIllumina | $40.7B |
| LNTHLantheus | $6.5B |
| IDXXIDEXX Laboratories | $44.1B |
| Peer median | $22.7B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Charles River Laboratories International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.